A-Alpha Bio is accelerating drug discovery by providing cell-based tools of protein interactions. Protein interactions govern all cellular processes and are therefore linked with disease. However, while predictive tools are now available for an individual protein structure, understanding protein interactions requires time-consuming experimentation. A-Alpha is circumventing this by generating high-quality protein-protein interaction data by measuring millions of protein-protein interactions at a time using AlphaSeq. AlphaSeq combines yeast two-hybrid technology with DNA barcodes to read out high-affinity interactions. This approach can be used to discover effective antibodies and degradable neo-substrates, engineer protein interfaces, and fuel predictive machine learning models.